We have a dedicated team who aim to provide a high level of care and support to people living with ALS. We are a regional centre that works closely with community teams ensuring that patients and their carers receive specialist knowledge and advice to support individuals. Sheffield is a major site for ALS clinical trials and clinical studies to improve symptom management and quality of life.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.